PCSK9 and atherosclerosis: Recent studies have clarified the role of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) in lipid metabolism, demonstrating its impact on low-density lipoprotein (LDL) levels, which are a key factor in the development of atherosclerosis and associated cardiovascular events.